Mucormycosis Treatment Market, By Species (Cunninghamella, Saksenaea, Rhizopus, Rhizomucor, Mucor, Lichtheimia, Apophysomyces And Others), By Diagnosis Method (Computed Tomography, Magnetic Resonance Imaging, Tissue Biopsy And Others.), By Treatment (Amphotericin B Therapy, Antifungal Medication, Surgery, And Others), By End-User, (Hospitals, Clinics, Research Organization, Medical Institute And Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI469121 | Publish Date: August 2023 | No. of Pages: 168

Global Mucormycosis Treatment Market Overview

Mucormycosis is a life-threatening invasive fungal disease with a high risk of morbidity and mortality despite treatment. In humans, mucormycosis manifests itself in a number of ways, especially in immunocompromised patients and those with diabetes. The most common syndromes caused by these fungi are debilitating rhino-orbital-cerebral and pulmonary infections. Mucormycosis is a fungal infection caused by a group of moulds known as mucormycetes. Furthermore, inhaling fungal spores from the air can damage the lungs and sinuses, and the disease can enter the body through wounds such as cuts, scrapes, burns, or other types of skin trauma. Mucormycosis normally has a poor prognosis. It is determined by a number of factors, including the patient's general health and ability to respond to treatments, the pace at which the diagnosis is made, and the care given. The Mucormycosis Treatment Market accounted for US$ 399.7 Million in 2020 and is estimated to be US$ 822.0 Million by 2030 and is anticipated to register a CAGR of 7.5 %.

Impact of Covid-19 pandemic on market

There has been an unprecedented two-to-three-fold increase in the number of cases of mucormycosis in the months after the Covid-19 hit, the majority of which have occurred in people recovering from Covid-19. As a result, some of the lives saved from Covid-19 are now succumbing to this extreme yet treatable fungus. This has added to the difficulty of combating the Covid threat. Mucor is more common in diabetics because it thrives on elevated blood sugar levels. Diabetic COVID patients on Steroids may have even higher sugar levels, which promotes mucor formation.

Global Mucormycosis Treatment Market Dynamics

Rising initiatives by government bodies

According to health officials in Maharashtra and Gujarat, cases of mucormycosis, a fungal infection, are on the rise among COVID-19 survivors, causing blindness, severe illness, and even death in some cases. The Gujarat government has started setting up separate wards in hospitals for COVID-19 survivors, and has procured 5,000 vials of a drug used in its care, in response to an increase in cases of mucormycosis, or "black fungus" infection. At least eight COVID-19 survivors have lost vision in one eye due to mucormycosis in Maharashtra, and 200 others are being treated.

Growth in business operations by emerging and small sized players

Increased occurrence of fungal infections, rise in incidence of immunological diseases, and greater access to a wide range of products are driving the mucormycosis market. Furthermore, the market's growth has been fueled by a growing geriatric population, increased government funding, and raising healthcare expenditure. However, treatment side effects and the prevalence of misbranded and spurious drugs can stifle market growth. Another factor driving the mucormycosis market is the growing number of diabetic patients, especially in Europe.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Mucormycosis Treatment Market Segmentation

 

Source: Prophecy Market Insights

The global Mucormycosis treatment market is segmented based on species, diagnosis method, treatment, end -user, and region.

On the basis of species, the global Mucormycosis treatment market is segmented into Cunninghamella, Saksenaea, Rhizopus, Rhizomucor, mucor, Lichtheimia,, Apophysomyces and  others. Based on site of diagnosis method, the target market is segmented into computed Tomography, magnetic resonance imaging, tissue biopsy and others. On the basis of treatment, the target market is segmented into amphotericin B therapy, antifungal medication, surgery and others. By End-use, the market is segmented into hospitals, clinics, research organization, medical institute and others.

Regional Insights:

On region the global Mucormycosis treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to lead the market because of its advanced health-care industry and massive mucormycosis patient population, North America controls a substantial portion of the global mucormycosis market. Europe accounts for a sizable portion of the global mucormycosis industry. This is attributed to advancements in surgical instrument technology and an increase in the occurrence of fungal infections.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Million & CAGR from 2020 – 2030

Market Segmentation

By species-  Cunninghamella, Saksenaea, Rhizopus, Rhizomucor,, mucor, Lichtheimia,, Apophysomyces and  others

By diagnosis method– Computed Tomography, Magnetic Resonance imaging, Tissue biopsy and others

By treatment– Amphotericin B therapy, Antifungal medication, Surgery and others

By End-use – Hospital, clinics, Research organization, medical institute and others

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the global Mucormycosis treatment market report based on species, diagnostic method, treatment, end-use, and region.

 

Global  Mucormycosis treatment Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Global Mucormycosis Treatment Market Key Players

The key players operating in the global mucormycosis treatment market includes Abbott Laboratories, Biocon Limited, Cadila Pharmaceuticals Limited, Novartis AG, F. Hoffman La Roche, Merck Sharp and Dohme, Mylan Labs, Bristol Myers Squibb, Bayer AG, Lonza Group, Sanofi, Johnson & Johnson, Pfizer Inc., and Gilead Sciences.

Global Mucormycosis Treatment Market Company Profile

  • Abbott laboratories
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Biocon Limited
  • Cadila Pharmaceuticals Limited
  • Novartis AG
  • F. Hoffman La Roche
  • Merck Sharp and Dohme
  • Mylan Labs
  • Bristol Myers Squibb
  • Bayer AG
  • Lonza Group
  • Sanofi
  • Johnson & Johnson
  • Pfizer Inc.
  • Gilead Sciences.

“*” marked represents similar segmentation in other categories in the respective section

Global Mucormycosis Treatment Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Mucormycosis Treatment Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Species
      • Market Snippet, By Diagnosis method
      • Market Snippet, By Treatment
      • Market Snippet, By End-User
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global Mucormycosis Treatment Market, By Species,  2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Cunninghamella
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Saksenaea
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Rhizopus
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Rhizomucor
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Mucor
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Lichtheimia
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Apophysomyces
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  6. Global Mucormycosis Treatment Market, By Diagnosis method, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Computed Tomography
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Magnetic Resonance Imaging
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Tissue biopsy
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  7. Global Mucormycosis Treatment Market, By Treatment, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Amphotericin B therapy
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Antifungal medication
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Surgery
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  8. Global Mucormycosis Treatment Market, By End-User, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Hospitals
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Clinics
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Research Organization
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Medical Institute
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030

 

  1. Global Mucormycosis Treatment Market, By Region, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Product, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Technology, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Patients, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Product, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Technology, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Patients, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Product, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Technology, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Patients, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Product, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Technology, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Patients, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Product, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Technology, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Patients, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  2. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  3. Company Profiles
  • Abbott laboratories
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Biocon Limited
  • Cadila Pharmaceuticals Limited
  • Novartis AG
  • F. Hoffman La Roche
  • Merck Sharp and Dohme
  • Mylan Labs
  • Bristol Myers Squibb
  • Bayer AG
  • Lonza Group
  • Sanofi
  • Johnson & Johnson
  • Pfizer Inc.
  • Gilead Sciences.

The Last Word

    • Future Impact
    • About Us
    • Contact

FAQs

The global Mucormycosis treatment market is segmented based on species, diagnosis method, treatment end-user and region.

Increased occurrence of fungal infections, rise in incidence of immunological diseases, and greater access to a wide range of products are driving the mucormycosis market.

North America is expected to lead the market with an estimated share of about xx% in the forecast period. Because of its advanced health-care industry and massive mucormycosis patient population, North America controls a substantial portion of the global mucormycosis market. Europe accounts for a sizable portion of the global mucormycosis industry.

Companies are continuously rising the production and supply. Furthermore, the market's growth has been fueled by a growing geriatric population, increased government funding, and raising healthcare expenditure.